FIELD: pharmaceuticals.
SUBSTANCE: compounds of formula I, formula Ia and formula Ib are described herein together with their analogues, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions and metabolites. The invention relates to specific new compounds specified in the claims, as well as to a pharmaceutical composition and method for the treatment and/or prevention of various diseases mediated by PRMT5.
EFFECT: new compounds that inhibit the PRMT5 enzyme which can be used for the treatment of diseases mediated by this activity, such as cancer and infectious diseases.
8 cl, 1 tbl, 167 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT METHOD | 2012 |
|
RU2621148C2 |
| TRICYCLIC CONDENSED DERIVATIVES OF PYRIDIN-2-ONE AND USE THEREOF AS BRD4 INHIBITORS | 2016 |
|
RU2734959C2 |
| NOVEL HETEROCYCLIC COMPOUNDS AS BRD4 INHIBITORS | 2016 |
|
RU2721120C2 |
| 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | 2021 |
|
RU2825312C1 |
| AGENTS CAUSING APOPTOSIS AND INTENDED FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2012 |
|
RU2594282C2 |
| NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITING NAMPT | 2011 |
|
RU2617643C2 |
| PYRAZOLE DERIVATIVE SUITABLE AS PI3K INHIBITOR | 2016 |
|
RU2710549C2 |
| 8-CARBAMOYL-2-(2,3-DI-SUBSTITUTED PYRID-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES AS APOPTOSIS-INDUCING AGENTS FOR CANCER TREATMENT | 2012 |
|
RU2625315C2 |
| SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE FOR TREATMENT OF PATHOLOGICAL CONDITIONS | 2017 |
|
RU2773333C2 |
| INDAZOLIE WNT SIGNAL PATHWAY INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | 2017 |
|
RU2682245C1 |
